Necrobiosis lipoidica is a rare inflammatory granulomatous skin disease of unknown etiology which is associated with diabetes mellitus in about 60 % of the patients. In up to 30 % of these patients extremely painful and often hard-to-heal ulcerations occur in the course of the disease. We present a new therapeutic option using adalimumab to treat refractory ulcerated necrobiosis lipoidica non diabeticorum. The clinical efficacy of adalimumab probably reflects an immunomodulatory effect through the specific TNF-α inhibition which is one central aspect of the underlying inflammation. Thus, adalimumab could represent promising new treatment option, especially for patients with otherwise therapy-refractory ulcerated necrobiosis lipoidica.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00105-013-2535-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ulcerative Necrobiosis Lipoidica Involving Atypical Site Over Upper Limb.
Indian J Dermatol
October 2024
Department of Pathology, Command Hospital, Kolkata, West Bengal, India.
Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica.
JID Innov
November 2024
Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.
Article Synopsis
- Drug repurposing offers a cost-effective strategy for developing therapies for rare diseases, which often face challenges in traditional drug development.
- This study used a new drug identification and repurposing pipeline to discover molecular drivers and potential therapies for psoriasis, leading to the identification of both known and novel disease mechanisms.
- The approach was further applied to necrobiosis lipoidica, revealing important disease drivers and potential treatments, demonstrating a high success rate in matching drugs to identified molecular targets.
The Differential Diagnosis of Leg Ulcers.
Dtsch Arztebl Int
November 2024
Department of Dermatology, Venereology and Allergology, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Vascular Medicine, Angiology, HELIOS Klinikum Krefeld GmbH, Krefeld, Germany.
Article Synopsis
- Leg ulcers, primarily located below the knee, can stem from various causes with around 80% resulting from chronic venous insufficiency (CVI) or peripheral arterial occlusive disease (PAOD), necessitating diverse medical specialists for treatment.
- The diagnostic approach follows the ABCDE rule, which includes personalized history-taking, bacteriological testing, clinical exams, and additional tests to accurately identify the cause of the ulcer, such as vascular issues or other diseases.
- Effective treatment relies on prompt differential diagnosis, highlighting the need for collaboration among different medical specialties due to the complexity of leg ulcers and the challenges posed by limited high-quality research.
Spatial transcriptomics reveals organized and distinct immune activation in cutaneous granulomatous disorders.
J Allergy Clin Immunol
November 2024
Department of Dermatology, Yale School of Medicine, New Haven, Conn; Department of Pathology, Yale School of Medicine, New Haven, Conn. Electronic address:
Article Synopsis
- Noninfectious cutaneous granulomatous disorders like cutaneous sarcoidosis, granuloma annulare, necrobiosis lipoidica, and necrobiotic xanthogranuloma exhibit distinct immune responses and histological features due to variations in macrophage inflammation.
- The study used spatial transcriptomics to analyze the immune activation patterns in these disorders, revealing that each condition has unique characteristics, such as polarized type 1 responses in cutaneous sarcoidosis and mixed type 1 and type 2 responses in granuloma annulare.
- Findings suggest that different immune activation patterns are associated with specific histological changes, highlighting the complexity and individuality of these inflammatory skin conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!